CSHP2501 - CME/CMLE - Challenges and Pitfalls in the Diagnosis of Myelodysplastic Syndrome with DDX41 Germline Predisposition

Course Description

Faculty/Authors

Jason X. Cheng, MD, PhD
Department of Pathology
University of Chicago

Lucy A. Godley, MD, PhD
Robert H Lurie Comprehensive Cancer Center
Northwestern University
Chicago, Illinois

CME or CMLE Credit: 2.0
Estimated Completion Time: 2 hours
Format: Online Educational Activity and Post Exam

Physician Competencies: Patient Care, Medical Knowledge

Eligibility for CME/CMLE credit: Max three attempts. You will have a maximum of three attempts to meet the following criteria:

Module ≥80% = CME credit
Module <80% = No CME credit, after a maximum of three attempts

Default Credit Type: None (You must meet the eligibility requirements in order to obtain CME credit.)

Accreditation Statement: The American Society for Clinical Pathology (ASCP) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education (CME) for physicians. This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME).

Credit Designation Statement: The American Society for Clinical Pathology (ASCP) designates this enduring material for a maximum of 2 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions

Review the Technical Considerations.
Click Go to Course to view an overview of the modules in this course.
Click Access to begin the course.
Choose the CME Activity to earn CME credit or the CMLE Activity to earn CMLE credit.

To claim CME credit for the exercise, do the following:

Review the Educational Activity.
Complete and submit the Post Exam. You will have a maximum of three attempts to obtain the required score. You will be notified if you have met the credit requirements after each attempt.
Submit the course Evaluation.
Enter the maximum number of credits offered and click Claim CME to register credit.

To claim CMLE credit for the exercise, do the following:

Review the Educational Activity.
Complete and submit the Post Exam.
Submit the course Evaluation.
Enter the maximum number of credits offered and click Claim CME to register credit.

Faculty Disclosures

Technical Considerations

Release Date: 2/28/2025
Review Date:
Expiration Date: 12/31/2027

Learning Objectives

Upon completion of this activity, you will be able to:

understand the rationale and importance for including the new entity of myeloid neoplasms (MNs) with germline predisposition in the revised 4th edition WHO Classification of Myeloid Neoplasms and Acute Leukemia and the update on this entity in the 5th edition WHO and the 2022 ICC classifications;

be familiar with the unique clinicopathologic features of DDX41 germline predisposition syndrome;

understand the importance of distinguishing between premalignant DDX41 germline predisposition syndrome and neoplastic myelodysplastic syndrome (MDS) with DDX41 germline predisposition;

recognize the diagnostic challenges and pitfalls in the diagnosis of MDS with deleterious DDX41 germline variants and their consequential impact on clinical management;

know how to avoid over- and under-diagnosing MDS in patients with deleterious DDX41 germline variants by using the diagnostic algorithm and pearls provided by this article; and

suggest and/or conduct molecular/genetic tests on appropriate samples for DDX41 and other germline predispositions based on their practical considerations and available information and resources.

Summary

Availability:

On-Demand

Credit Offered:

2 CME Credits

2 CMLE Credits